Multi-Receptor Opioid Reversal Composition for Fentanyl Overdose

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for opioid and opioid-related overdoses, particularly those induced by fentanyl and its analogues, are inadequate due to the unique side effects profile of these substances, which conventional mu-opioid receptor antagonists like naloxone cannot effectively address, leading to high mortality rates and lack of FDA-approved pharmacotherapies for rescue treatment.

Innovation Solution

Development of a new generation of opioid reversal drugs that simultaneously antagonize mu opioid receptors and other receptor subtypes, including kappa and delta receptors, as well as alpha adrenergic and cholinergic receptors, to effectively treat fentanyl-induced muscle rigidity, respiratory depression, and laryngospasm, using combinations of compounds such as mu opioid receptor antagonists, alpha-1 adrenergic antagonists, and cholinergic agents.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional mu-opioid receptor antagonists like naloxone are used to treat opioid overdose, then respiratory depression can be reversed, but fentanyl-induced muscle rigidity, laryngospasm, and other unique side effects cannot be effectively addressed

Engineering Contradiction:

Improveeffectiveness of overdose treatmentVSAvoidability to address unique side effect profile

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent develops a multi-component pharmacological composition that simultaneously targets multiple receptor systems (mu-opioid, alpha-adrenergic, and cholinergic receptors) to address the diverse physiological effects of fentanyl overdose. This multi-functional approach allows a single treatment regimen to reverse respiratory depression, relax muscle rigidity, and treat laryngospasm, making the therapy adaptable to the complete side effect profile of fentanyl analogues

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Productivity

If high dose naloxone is administered to treat fentanyl overdose, then respiratory depression may be partially reversed, but mortality rates remain high due to inability to treat muscle rigidity and laryngospasm

Engineering Contradiction:

Improverescue treatment efficacyVSAvoidmortality from unique side effects

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent segments the treatment into distinct pharmacological components, each targeting a specific physiological system affected by fentanyl overdose. The composition includes mu-opioid receptor antagonists for respiratory depression, alpha-adrenergic antagonists for muscle rigidity, and cholinergic agents for laryngospasm. This segmented approach allows each component to effectively address its specific target, collectively reducing mortality from all unique side effects

Inventive Principle:

Principle #1Segmentation

3Device complexity

If single-target opioid antagonists are used, then the treatment mechanism is simple and well-understood, but the therapy fails to address the complex multi-receptor effects of fentanyl and its analogues

Engineering Contradiction:

Improvetreatment mechanism complexityVSAvoidcompleteness of overdose reversal

Core Design Contradiction:

Device complexityVSReliability

Solution Approach 1:

The patent creates a composite pharmacological treatment by combining multiple agents with different mechanisms of action into a single formulation. This composite composition integrates mu-opioid antagonists, alpha-adrenergic blockers, and cholinergic medications, allowing the treatment to address the complex multi-receptor effects of fentanyl analogues while maintaining a unified administration protocol that simplifies clinical use

Inventive Principle:

Principle #40Composite materials

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The multi-systems treatment approach significantly reduces mortality from fentanyl and fentanyl analogue overdoses by effectively reversing respiratory depression, muscle rigidity, and laryngospasm, providing both immediate reversal and prophylactic solutions for first responders and individuals exposed to these substances.

Implementation Method 1

mu opioid receptor antagonists like naloxone

Methodology Applied

Scientific EffectReceptor antagonism:

Implementation Method 2

alpha-1 adrenergic antagonists

Methodology Applied

Scientific EffectReceptor antagonism:

Implementation Method 3

cholinergic agents

Methodology Applied

Scientific EffectReceptor agonism/antagonism:

Data Source

PatentUS20240325380A1Compositions for opiate and opioid prevention and reversal, and methods of their use

Publication Date: 2024.10.03 TMTRX INC

AI summary

Compositions are provided including a Mu opioid receptor antagonist, and an α2-adrenergic receptor agonist; or an α1 adrenergic receptor antagonist, together with one or more of a mu (or opioid receptor subtype) antagonist or agonist, (2) a vasopressor, (3) an anticholinergic agent and/or cholinergic agents, (4) a combined alpha-1 adrenergic antagonist and anticholinergic, (5) a paralytic or muscle relaxant, (6) a respiratory accelerant, (7) a GABA complex antagonist, (8) an anti-seizure/membrane stabilizer agent, (9) an α1 adrenergic receptor agonist, and/or (10) an α2 adrenergic receptor agonist; and a pharmaceutically acceptable carrier. Also provided are methods of preventing or reversing effects in a subject (including muscle and chest wall rigidity, laryngospasm, WCS, and/or respiratory depression) arising from intentional or accidental opioid or opiate exposure.